More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$245698893
EPS
-1.19
P/E ratio
--
Price to sales
1.05
Dividend yield
--
Beta
0.593887
Previous close
$3.94
Today's open
$3.91
Day's range
$3.86 - $4.06
52 week range
$2.56 - $6.67
show more
CEO
Miguel Martin
Employees
1073
Headquarters
Edmonton, Alberta
Exchange
NASDAQ Capital Market
Shares outstanding
61956924
Issue type
Common Stock
Healthcare
Pharmaceuticals
AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID
Curaleaf's self-serving portrayal of our business is an attempt to acquire Aurora's world class EU-GMP manufacturing facilities and global medical cannabis footprint at the lowest price possible Aurora's international strategy is working; net revenue is up 17%YOY Contrary to Curaleaf's inaccurate statements, Aurora's high margin German business is growing and continues to be a key driver of Aurora's international growth strategy Shareholders are advised to TAKE NO ACTION pending formal recommendation from the Board and Special Committee. Offer remains open for at least 105 days from the launch of the Hostile Bid Questions about the Offer or would like to stay informed?
PRNewsWire • Aug 24, 2026

Curaleaf Responds to Aurora Cannabis' Latest Attempt to Deflect From Shareholder Value Creation
Aurora's selective statistics and misleading characterization of engagement do not obscure years of underperformance and lost shareholder value Curaleaf reiterates its willingness to meet anytime to discuss a deal in the best interests of shareholders STAMFORD, Conn., Aug. 24, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s (TSX: ACB) (NASDAQ: ACB) ("Aurora") latest public statements regarding Curaleaf's offer for Aurora: "Aurora's hollow protests and completely misleading statistics change nothing about reality: if its multi-year turnaround strategy were delivering the value management claims, the company's valuation would reflect it.
PRNewsWire • Aug 24, 2026

The Cannabis M&A Wave Is Here. Curaleaf Proved It.
Green Thumb Industries is one of the few U.S. cannabis companies that has been consistently profitable. The company grew revenue and earnings in the second quarter.
The Motley Fool • Aug 23, 2026

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.
Curaleaf has made an unsolicited bid for Aurora Cannabis. Aurora recently completed its acquisition of Safari Flower.
The Motley Fool • Aug 21, 2026

Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?
Curaleaf reiterated the offer it made public last week. Aurora stock continues to trade at a discount to the base offer price.
The Motley Fool • Aug 20, 2026

Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market
EDMONTON, AB, Aug. 19, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy (the "Companies"). "The acquisition of Internode Pharma Limited and HAP Pharma Limited mark a further strategic milestone for Aurora as we continue to purposefully invest in expanding our leadership in the rapidly growing international medical cannabis market.
PRNewsWire • Aug 19, 2026

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD
Shares of Tilray Brands (NASDAQ:TLRY) are up 6% to $4.75 Wednesday afternoon, participating in a broad bid for beaten-down speculative names.
24/7 Wall Street • Aug 19, 2026

AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC.
Curaleaf's decision to launch a hostile takeover bid is designed to pressure Aurora's shareholders into a short-term decision for the benefit of Curaleaf shareholders. Curaleaf's actions and comments reflect its objective: to acquire, at the lowest price possible, Aurora's market-leading EU-GMP facilities and global medical cannabis platform.
PRNewsWire • Aug 19, 2026

Curaleaf CEO talks unsolicited offer to buy Aurora Cannabis
Curaleaf Chairman and CEO Boris Jordan joins 'Fast Money' to talk the cannabis company's bid for Aurora Cannabis.
CNBC Television • Aug 18, 2026

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?
Curaleaf's bid signals cannabis consolidation is accelerating. Canopy Growth could emerge as another takeover candidate.
The Motley Fool • Aug 16, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Aurora Cannabis Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.